---
figid: PMC4367559__tlcr-01-03-179-f2
figlink: /pmc/articles/PMC4367559/figure/f2/
number: F2
caption: Schematic representation of mechanisms of resistance due to MET/HGF pathway
  and potential interventional strategies. Chemotherapy and radiotherapy damage DNA
  which in-turn increases nuclear factor kappa B (NF-κB) mediated increased expression
  of HGF and MET. MET [I] and/or HGF [II] over-expression are major mechanisms of
  resistance due to MET/HGF axis against contemporary therapies. VEGF inhibition can
  cause hypoxia and increased hypoxia-inducible factor-alpha (HIF-α) mediated HGF
  and MET expression. Rarely, mutations in the kinase domain [III] can cause constitutional
  activation of MET signaling and contribute to increased resistance. In gefitinib,
  erlotinib, cetuximab and bevacizumab resistant tumors, MET/HGF activates oncogenic
  signaling via Mitogen-activated protein kinase (ERK/MAPK) pathway, the Phosphatidylinositol
  3 kinase (PI3K-AKT) pathway and the Phospholipase-Cγ (PLC-γ) pathway. The MET/HGF
  inhibition by HGF antagonists [A], anti-MET antibody [B] or small molecule receptor
  tyrosine kinase inhibitor (SmRTKI) [C] can help overcome resistance.
pmcid: PMC4367559
papertitle: Role of HGF/MET axis in resistance of lung cancer to contemporary management.
reftext: Kanwal Pratap Singh Raghav, et al. Transl Lung Cancer Res. 2012 Sep;1(3):179-193.
pmc_ranked_result_index: '26281'
pathway_score: 0.9692312
filename: tlcr-01-03-179-f2.jpg
figtitle: Mechanisms of resistance due to MET/HGF pathway and potential interventional
  strategies
year: '2012'
organisms:
- Homo sapiens
ndex: d5216da8-dec6-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4367559__tlcr-01-03-179-f2.html
  '@type': Dataset
  description: Schematic representation of mechanisms of resistance due to MET/HGF
    pathway and potential interventional strategies. Chemotherapy and radiotherapy
    damage DNA which in-turn increases nuclear factor kappa B (NF-κB) mediated increased
    expression of HGF and MET. MET [I] and/or HGF [II] over-expression are major mechanisms
    of resistance due to MET/HGF axis against contemporary therapies. VEGF inhibition
    can cause hypoxia and increased hypoxia-inducible factor-alpha (HIF-α) mediated
    HGF and MET expression. Rarely, mutations in the kinase domain [III] can cause
    constitutional activation of MET signaling and contribute to increased resistance.
    In gefitinib, erlotinib, cetuximab and bevacizumab resistant tumors, MET/HGF activates
    oncogenic signaling via Mitogen-activated protein kinase (ERK/MAPK) pathway, the
    Phosphatidylinositol 3 kinase (PI3K-AKT) pathway and the Phospholipase-Cγ (PLC-γ)
    pathway. The MET/HGF inhibition by HGF antagonists [A], anti-MET antibody [B]
    or small molecule receptor tyrosine kinase inhibitor (SmRTKI) [C] can help overcome
    resistance.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HIF1A
  - HGF
  - PIK3CD
  - MAPK12
  - MET
  - NFKB1
  - MAPK13
  - MAPK1
  - PIK3CA
  - HIF3A
  - AKT2
  - MAPK3
  - MAPK8
  - PIK3CB
  - EGF
  - AKT1
  - AKT3
  - MAPK11
  - VEGFA
  - EGFR
  - MAPK14
  - PIK3R4
  - MAPK9
  - KDR
  - PIK3CG
  - EPAS1
  - PIK3R3
  - AIFM1
  - PIK3R5
  - PIK3R6
  - MAPK10
  - Cancer
genes:
- word: HIF-a
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: HIF-a
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: VEGFR-2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: HIF-a
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AIF
  symbol: AIF
  source: hgnc_alias_symbol
  hgnc_symbol: AIFM1
  entrez: '9131'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: ERK/MAPK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK/MAPK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ERK/MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC4367559__F2
redirect_from: /figures/PMC4367559__F2
figtype: Figure
---
